Bevacizumab beyond progression in breast cancer
Mené sur 494 patientes atteintes d'un cancer du sein HER2- métastatique ou récidivant ayant progressé après un traitement combinant bevacizumab et chimiothérapie, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de bevacizumab à une chimiothérapie de deuxième ligne
Angiogenesis is the sprouting of new blood vessels from pre-existing ones, and is considered to be a prerequisite for the growth of both primary tumours and metastases. VEGF is a crucial factor involved in angiogenesis. Suppression of VEGF signalling in preclinical models results in suppression of tumour growth. These findings led to the clinical development of VEGF-targeted therapies, such as the VEGF-neutralising antibody bevacizumab. However, despite showing efficacy in other cancer types,...
The Lancet Oncology , commentaire, 2013